Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12987414 | 0.86 | LMNA (0.47) | LMNAEGLN1ALKBH5SUCNR1CAMK2A | |
| SCHEMBL15621601 | 0.79 | LMNA (0.40) | LMNAEGLN1ALKBH5SUCNR1KMT2A | |
| SCHEMBL149291 | 0.77 | LMNA (0.38) | LMNAEGLN1ALKBH5SUCNR1CAMK2A | |
| SCHEMBL12886188 | 0.77 | ALDH1A1 (0.50) | LMNAEGLN1ALKBH5SUCNR1KMT2A | |
| SCHEMBL460115 | 0.77 | LMNA (0.38) | LMNAEGLN1ALKBH5SUCNR1CAMK2A | |
| SCHEMBL6584835 | 0.77 | LMNA (0.40) | LMNAEGLN1ALKBH5SUCNR1KMT2A | |
| SCHEMBL26342933 | 0.77 | LMNA (0.38) | LMNAEGLN1ALKBH5SUCNR1CAMK2A | |
| SCHEMBL346110 | 0.75 | FFAR3 (0.48) | LMNAEGLN1ALKBH5SUCNR1KMT2A | |
| SCHEMBL26971247 | 0.75 | LMNA (0.52) | LMNAEGLN1ALKBH5SUCNR1KMT2A | |
| SCHEMBL38157 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-0037422-A4 | FLUORO-SUBSTITUTED PROSTAGLANDINS AND PROSTACYCLINS. | UNIV CHICAGO (US) | 1982-01-26 | — | — | EP | disclosed |
| EP-0037422-A1 | FLUORO-SUBSTITUTED PROSTAGLANDINS AND PROSTACYCLINS | UNIVERSITY OF CHICAGO (US) | 1981-10-14 | — | — | EP | disclosed |
| WO-1981001002-A1 | FLUORO-SUBSTITUTED PROSTAGLANDINS AND PROSTACYCLINS | UNIV CHICAGO (US) | 1981-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | LMNA 3592/4885EGLN1 2167/4885ALKBH5 161/4885 |
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | LMNA 3592/4885EGLN1 2167/4885ALKBH5 161/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | LMNA 3739/4885EGLN1 1691/4885ALKBH5 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.